Skip to main content
Erschienen in: Journal of Translational Medicine 1/2016

Open Access 01.12.2016 | Erratum

Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines

verfasst von: Silvia Boero, Anna Morabito, Barbara Banelli, Barbara Cardinali, Beatrice Dozin, Gianluigi Lunardi, Patrizia Piccioli, Sonia Lastraioli, Roberta Carosio, Sandra Salvi, Alessia Levaggi, Francesca Poggio, Alessia D’Alonzo, Massimo Romani, Lucia Del Mastro, Alessandro Poggi, Maria Pia Pistillo

Erschienen in: Journal of Translational Medicine | Ausgabe 1/2016

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The online version of the original article can be found under doi:10.​1186/​s12967-015-0680-0.
The online version of the original article can be found at http://​dx.​doi.​org/​10.​1186/​s12967-015-0680-0.

Erratum to: J Transl Med (2015) 13:324 DOI 10.1186/s12967-015-0680-0

It has come the publisher’s attention that the original version of this article [1] unfortunately contained an error. In Table 3, first column, the FcγRIIA 131 H>R genotypes were incorrectly labelled. In particular, V/V should have read H/H, V/F should have read H/R and F/F should have read R/R. Please note that this correction does not change the genotype numerical values of FcγRIIA polymorphism. The correct Table 3 has been published as Table 1 in this Erratum.
Table 1
Genotypic and allelic frequencies of FcγRIIIA and FcγRIIA polymorphisms in breast cancer patients and healthy controls
Genotypes
n (%)
P *
Alleles
n (frequency)
NEO (n = 15)
MTS (n = 10)
CTR (n = 33)
NEO (2n = 30)
MTS (2n = 20)
CTR (2n = 66)
FcγRIIIA 158V>F
   
FcγRIIIA 158V>F
  
 V/V
4 (26.7)
3 (30.0)
6 (18.2)
0.741
 V
13 (0.43)
8 (0.40)
26 (0.39)
0.934
 V/F
5 (33.3)
2 (20.0)
14 (42.4)
 
 F
17 (0.57)
12 (0.60)
40 (0.60)
 
 F/F
6 (40.0)
5 (50.0)
13 (39.4)
      
 HWE
P = 0.213
P = 0.065
P = 0.522
      
FcγRIIA 131H>R
   
FcγRIIA 131H>R
  
 H/H
3 (20.0)
4 (40.0)
9 (27.3)
0.499
 H
14 (0.47)
10 (0.50)
35 (0.53)
0.843
 H/R
8 (53.3)
2 (20.0)
17 (51.5)
 
 R
16 (0.53)
10 (0.50)
31 (0.47)
 
 R/R
4 (26.7)
4 (40.0)
7 (21.2)
      
 HWE
P = 0.782
P = 0.058
0.845
      
Genotyping of FcγRIIIA 158V>F was performed by a newly developed PSQ method after pre-amplification of FcγRIIIA gene. Genotyping of FcγRIIA 131H>R was performed by T-ARMS PCR and SBT. Conventionally, the 158V>F variant corresponds to the G>T SNP [i.e. guanine corresponding to valine (V) and thymine corresponding to phenylalanine (F)] and the 131H>R SNP corresponds to the A>G SNP [i.e. adenine corresponding to histidine (H) and guanine corresponding to arginine (R)]
Comparison of FcγR genotypic and allelic frequencies between patients and control subjects was estimated using the Pearson’s χ2 test (P* value) and the Fisher’s test (P° value), respectively. Statistical significance: P < 0.05
NEO neoadjuvant, MTS metastatic, CTR controls, HWE Hardy–Weinberg equilibrium. HWE was tested by the Pearson’s χ2 test (P < 0.05 indicates lack of HWE)
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Boero S, Morabito A, Banelli B, Cardinali B, Dozin B, Lunardi G, Piccioli P, Lastraioli S, Carosio R, Salvi S, Levaggi A, Poggio F, D’Alonzo A, Romani M, Del Mastro L, Poggi A, Pistillo MP. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. J Transl Med. 2015;13:324.PubMedCentralCrossRefPubMed Boero S, Morabito A, Banelli B, Cardinali B, Dozin B, Lunardi G, Piccioli P, Lastraioli S, Carosio R, Salvi S, Levaggi A, Poggio F, D’Alonzo A, Romani M, Del Mastro L, Poggi A, Pistillo MP. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. J Transl Med. 2015;13:324.PubMedCentralCrossRefPubMed
Metadaten
Titel
Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines
verfasst von
Silvia Boero
Anna Morabito
Barbara Banelli
Barbara Cardinali
Beatrice Dozin
Gianluigi Lunardi
Patrizia Piccioli
Sonia Lastraioli
Roberta Carosio
Sandra Salvi
Alessia Levaggi
Francesca Poggio
Alessia D’Alonzo
Massimo Romani
Lucia Del Mastro
Alessandro Poggi
Maria Pia Pistillo
Publikationsdatum
01.12.2016
Verlag
BioMed Central
Erschienen in
Journal of Translational Medicine / Ausgabe 1/2016
Elektronische ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-016-0779-y

Weitere Artikel der Ausgabe 1/2016

Journal of Translational Medicine 1/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.